Cadrenal Therapeutics (CVKD) Accounts Payables (2022 - 2026)
Cadrenal Therapeutics (CVKD) posted Accounts Payables of $824809.0 for Q1 2026, up 26.76% sequentially from $650663.0 in Q4 2025, and down 35.48% YoY from $1.3 million in Q1 2025.
Cadrenal Therapeutics (CVKD) Accounts Payables (2022 - 2026) Analysis & Trends
Cadrenal Therapeutics has reported Accounts Payables for 5 years, with the latest figure at $824809.0 in Q1 2026.
- Quarterly Accounts Payables fell 35.48% year-over-year to $824809.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $824809.0 (down 35.48% YoY) and the FY2025 annual result came in at $650663.0, down 56.69% from the prior year.
- Accounts Payables improved to $824809.0 in Q1 2026 per CVKD's latest filing, from $650663.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $1.5 million in Q4 2024 and troughed at $78139.0 in Q2 2023.
- A 5-year average of $595312.3 and a median of $555475.0 in 2024 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2023 and 2024: Accounts Payables tumbled 58.68% in 2023, then soared 872.01% in 2024.
- Over 5 years, Accounts Payables stood at $404897.0 in 2022, then tumbled by 58.68% to $167319.0 in 2023, then surged by 797.97% to $1.5 million in 2024, then sank by 56.69% to $650663.0 in 2025, then advanced by 26.76% to $824809.0 in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $824809.0, $650663.0, and $614127.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Cadrenal Therapeutics | 4.59 Mn | 2.19 Mn | - | 871,913.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 871,913.00 |
| Mar 31, 2026 | 824,809.00 |
| Dec 31, 2025 | 650,663.00 |
| Sep 30, 2025 | 614,127.00 |
| Jun 30, 2025 | 895,609.00 |
| Mar 31, 2025 | 1.28 Mn |
| Dec 31, 2024 | 1.50 Mn |
| Sep 30, 2024 | 496,823.00 |
| Jun 30, 2024 | 759,518.00 |
| Mar 31, 2024 | 400,373.00 |
| Dec 31, 2023 | 167,319.00 |
| Sep 30, 2023 | 141,658.00 |
| Jun 30, 2023 | 78,139.00 |
| Mar 31, 2023 | 119,567.00 |
| Dec 31, 2022 | 404,897.00 |